Bulletin

Investor Alert

Tokyo Markets Close in:

Currencies Europe Markets London Markets

Keros Therapeutics Inc.

NAS: KROS

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Keros Therapeutics Inc.

After Hours

KROS

/zigman2/quotes/217766474/composite

67.20

Change

0.00 0.00%

Volume

Volume 432

Jan 20, 2021, 4:06 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/217766474/composite

Previous close

$ 68.39

$ 67.20

Change

-1.19 -1.74%

Day low

Day high

$66.64

$69.25

Open: 68.83

52 week low

52 week high

$19.10

$88.80

Market cap

$1.38B

Average volume

225,217

P/E ratio

N/A

Rev. per Employee

$434,783

EPS

-2.05

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/kros

MarketWatch News on KROS

Keros Therapeutics sets IPO terms, expects to raise up to $80 million

5:32 a.m. April 1, 2020

- Tomi Kilgore
Keros Therapeutics sets IPO terms to raise up to $80 mln

5:25 a.m. April 1, 2020

- Tomi Kilgore

/news/nonmarketwatch/company/us/kros

Other News on KROS

Seeking Alpha Catalyst Watch

3:30 p.m. Dec. 4, 2020

- Seeking Alpha
Keros Therapeutics prices equity offering at $50

5:19 a.m. Nov. 13, 2020

- Seeking Alpha
OraSure's Emergency Use Authorization, And Other News: The Good, Bad And Ugly Of Biopharma

6:26 a.m. Oct. 22, 2020

- Seeking Alpha
Dosing underway for Keros Therapeutics's KER-050 in mid-stage for myelodysplastic syndromes study

12:45 p.m. Oct. 20, 2020

- Seeking Alpha
10-Q: KEROS THERAPEUTICS, INC.

6:23 a.m. Aug. 13, 2020

- Edgar Online - (EDG = 10Q, 10K)
Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher

7:34 a.m. June 24, 2020

- Zacks.com
Keros Therapeutics (KROS) Presents At European Hematology Association Congress - Slideshow

1:46 p.m. June 12, 2020

- Seeking Alpha
Keros Therapeutics reports KER-050 data in human and animal trials

9:54 a.m. June 12, 2020

- Seeking Alpha
10-Q: KEROS THERAPEUTICS, INC.

6:18 a.m. May 22, 2020

- Edgar Online - (EDG = 10Q, 10K)
SunTrust sees 90% upside in Relmada Therapeutics in premarket analyst action

6:29 a.m. May 4, 2020

- Seeking Alpha
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO

2:31 p.m. April 21, 2020

- GuruFocus.com
Weekly CEO Buys Highlight

7:40 a.m. April 20, 2020

- GuruFocus.com
Insiders Who Believe Their Stock Has Bottomed - Weekly Update (04/09/20 - 04/16/20)

5:09 p.m. April 17, 2020

- Seeking Alpha
IPO Update: Keros Therapeutics Proposes IPO Terms

9:55 a.m. April 2, 2020

- Seeking Alpha
Keros Therapeutics Starts U.S. IPO Effort Amid Market Turmoil

12:20 p.m. March 17, 2020

- Seeking Alpha
Keros Therapeutics on deck for IPO

9:07 p.m. March 16, 2020

- Seeking Alpha

/news/pressrelease/company/us/kros

Press Releases on KROS

Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index

8:00 a.m. Dec. 21, 2020

- GlobeNewswire
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors

9:47 a.m. Dec. 17, 2020

- GlobeNewswire
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

8:00 a.m. Dec. 7, 2020

- GlobeNewswire
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

4:01 p.m. Nov. 17, 2020

- GlobeNewswire
Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

8:26 a.m. Nov. 16, 2020

- GlobeNewswire
Keros Therapeutics Announces Pricing of Public Offering of Common Stock

10:11 p.m. Nov. 12, 2020

- GlobeNewswire
Keros Therapeutics Announces Proposed Public Offering of Common Stock

5:12 p.m. Nov. 10, 2020

- GlobeNewswire
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

4:17 p.m. Nov. 10, 2020

- GlobeNewswire
Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies' IPO

8:00 a.m. Nov. 9, 2020

- GlobeNewswire
Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies' IPO

8:00 a.m. Nov. 9, 2020

- Globe Newswire
Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies' IPO

8:00 a.m. Nov. 9, 2020

- GlobeNewswire
Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

4:01 p.m. Nov. 4, 2020

- GlobeNewswire
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)

7:01 a.m. Oct. 20, 2020

- GlobeNewswire
Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

6:10 a.m. Sept. 14, 2020

- GlobeNewswire
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting

3:02 p.m. Sept. 11, 2020

- GlobeNewswire
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

6:01 a.m. Aug. 13, 2020

- GlobeNewswire
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series

7:12 a.m. Aug. 10, 2020

- GlobeNewswire
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update

7:00 a.m. Aug. 4, 2020

- GlobeNewswire
Keros Therapeutics Set to Join Russell 2000(R) Index

6:01 a.m. June 26, 2020

- GlobeNewswire
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting

6:01 a.m. June 12, 2020

- GlobeNewswire
Loading more headlines...

Rates »

Mortgage Equity Savings Auto

National averages from Bankrate.com

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Keros Therapeutics Inc.

MarketWatch News on KROS

Other News on KROS

Press Releases on KROS

Rates »

Latest News

dow

nasdaq

s&p 500

Kiosk